Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,994,056 shares, a drop of 44.0% from the March 15th total of 3,559,666 shares. Currently, 5.7% of the shares of the company are sold short. Based on an average trading volume of 1,411,641 shares, the days-to-cover ratio is currently 1.4 days.

Analysts Set New Price Targets

Several research firms have recently issued reports on MDCX. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a report on Friday. D. Boral Capital reissued a “buy” rating and issued a $27.00 target price on shares of Medicus Pharma in a research note on Thursday, March 19th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medicus Pharma has an average rating of “Hold” and an average target price of $23.50.

Medicus Pharma Price Performance

MDCX traded down $0.01 during mid-day trading on Monday, hitting $0.40. The stock had a trading volume of 990,869 shares, compared to its average volume of 1,250,944. The stock’s fifty day simple moving average is $0.79 and its 200-day simple moving average is $1.55. The firm has a market capitalization of $15.82 million, a price-to-earnings ratio of -0.14 and a beta of 1.16. Medicus Pharma has a 1-year low of $0.37 and a 1-year high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Thursday, March 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.50). As a group, research analysts expect that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Medicus Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Medicus Pharma in the 2nd quarter valued at about $41,000. HRT Financial LP bought a new position in Medicus Pharma in the 4th quarter valued at about $42,000. Osaic Holdings Inc. grew its holdings in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares during the last quarter. Finally, Brave Asset Management Inc. bought a new stake in Medicus Pharma during the 3rd quarter worth approximately $46,000.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.